TipRanks
Advertisement
Advertisement

SNDX Stock Latest News

Axatilimab’s Emerging IPF and cGVHD Profile Supports Buy Rating on SNDX, With Price Target Unchanged at $57
RatingsAxatilimab’s Emerging IPF and cGVHD Profile Supports Buy Rating on SNDX, With Price Target Unchanged at $57
4d ago
SNDX
Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
PremiumStock Analysis & Ideas
Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
1M ago
BMEA
SNDX
Syndax price target lowered to $33 from $37 at UBS
PremiumThe Fly
Syndax price target lowered to $33 from $37 at UBS
1M ago
SNDX
Syndax Pharmaceuticals Earnings Call Signals Strong Momentum
PremiumCompany Announcements
Syndax Pharmaceuticals Earnings Call Signals Strong Momentum
1M ago
SNDX
Syndax price target lowered to $40 from $44 at JPMorgan
PremiumThe Fly
Syndax price target lowered to $40 from $44 at JPMorgan
2M ago
SNDX
Syndax Buy Rating Reaffirmed as Analyst Sees Transitory Demand Weakness, Strong Menin Positioning and Pipeline Catalysts Supporting Unchanged $57 Target
PremiumRatingsSyndax Buy Rating Reaffirmed as Analyst Sees Transitory Demand Weakness, Strong Menin Positioning and Pipeline Catalysts Supporting Unchanged $57 Target
2M ago
SNDX
Syndax price target lowered to $38 from $40 at H.C. Wainwright
Premium
The Fly
Syndax price target lowered to $38 from $40 at H.C. Wainwright
2M ago
SNDX
Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Trajectory and Potential $2B Peak U.S. Sales
Premium
Ratings
Phil Nadeau Reiterates Buy on Syndax, Citing Strong Revuforj Trajectory and Potential $2B Peak U.S. Sales
2M ago
SNDX
Syndax reports Q2 EPS (55c), consensus (44c)
PremiumThe Fly
Syndax reports Q2 EPS (55c), consensus (44c)
2M ago
SNDX
SNDX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
SNDX Upcoming Earnings Report: What to Expect?
2M ago
SNDX
Syndax: Expanding Pipeline and Upcoming Axatilimab IPF Data Support Buy Rating and $29 Price Target Upside
PremiumRatings
Syndax: Expanding Pipeline and Upcoming Axatilimab IPF Data Support Buy Rating and $29 Price Target Upside
3M ago
SNDX
Syndax: Strengthening Pipeline and R&D Outlook Support Buy Rating and Unchanged $34 Price Target
PremiumRatings
Syndax: Strengthening Pipeline and R&D Outlook Support Buy Rating and Unchanged $34 Price Target
3M ago
SNDX
Syndax: Advancing Menin Inhibitor and Fibrosis/Oncology Pipeline Supports High-Risk, High-Reward Buy Rating
PremiumRatingsSyndax: Advancing Menin Inhibitor and Fibrosis/Oncology Pipeline Supports High-Risk, High-Reward Buy Rating
3M ago
SNDX
Syndax: Expanding High-Potential Pipeline and Disciplined Strategy Support Unchanged $40 Price Target and Buy Rating
Premium
Ratings
Syndax: Expanding High-Potential Pipeline and Disciplined Strategy Support Unchanged $40 Price Target and Buy Rating
3M ago
SNDX
Syndax Showcases Late-Stage Pipeline, Expands R&D Strategy
Premium
Company Announcements
Syndax Showcases Late-Stage Pipeline, Expands R&D Strategy
3M ago
8K
SNDX
Syndax price target lowered to $31 from $34 at Guggenheim
PremiumThe Fly
Syndax price target lowered to $31 from $34 at Guggenheim
4M ago
KURA
SNDX
Syndax Buy Rating Reiterated as Revuforj Data Strengthens AML Profile; $40 Price Target Maintained
PremiumRatings
Syndax Buy Rating Reiterated as Revuforj Data Strengthens AML Profile; $40 Price Target Maintained
4M ago
SNDX
Syndax presents data from SAVE trial at EHA
PremiumThe Fly
Syndax presents data from SAVE trial at EHA
4M ago
SNDX
Syndax Pharmaceuticals Reports New Significant Financial Obligation Agreement
PremiumCompany Announcements
Syndax Pharmaceuticals Reports New Significant Financial Obligation Agreement
4M ago
8K
SNDX
Syndax Shareholders Approve 2026 Equity and ESPP Plans
PremiumCompany AnnouncementsSyndax Shareholders Approve 2026 Equity and ESPP Plans
4M ago
8K
SNDX
Analyst Reiterates Buy on Syndax, Sees Durable Revuforj Upside with Unchanged $34 Price Target
Premium
Ratings
Analyst Reiterates Buy on Syndax, Sees Durable Revuforj Upside with Unchanged $34 Price Target
4M ago
SNDX
Syndax Pharmaceuticals Prices $250 Million Convertible Senior Notes
Premium
Company Announcements
Syndax Pharmaceuticals Prices $250 Million Convertible Senior Notes
4M ago
8K
SNDX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >